The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 9.30 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.54 — no flag raisedOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as REGENERON PHARMACEUTICALS, INC. reports it. History and quarterly detail are in the app.
- Collaboration revenue$7.3B
- Net product sales$6.3B
- Regeneron's share of profits$5.2B
- Reimbursement of commercialization-related expenses$729.3M
- Other revenue$702.6M
Leadership changes
From REGENERON PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- Robert E. Landry · Chief Financial Officer · departureeff. 2023-09-08
- Marc Tessier-Lavigne · director · departureeff. 2023-09-01
- David P. Schenkein · director · appointment
Latest filings
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-04-29
- 10-Q · Quarterly report2026-04-29
- DEF 14A · Annual proxy (pay & governance)2026-04-24
- 8-K · Company announcement2026-04-08
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about REGENERON PHARMACEUTICALS, INC., every answer cited🔒
- The Intelligence Brief — added when REGENERON PHARMACEUTICALS, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.